CN117298092A - 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 - Google Patents

具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 Download PDF

Info

Publication number
CN117298092A
CN117298092A CN202311053636.8A CN202311053636A CN117298092A CN 117298092 A CN117298092 A CN 117298092A CN 202311053636 A CN202311053636 A CN 202311053636A CN 117298092 A CN117298092 A CN 117298092A
Authority
CN
China
Prior art keywords
treatment
day
diseases
compound
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311053636.8A
Other languages
English (en)
Chinese (zh)
Inventor
董宇红
张俊雄
林胜堂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunregen Healthcare AG
Original Assignee
Sunregen Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunregen Healthcare AG filed Critical Sunregen Healthcare AG
Publication of CN117298092A publication Critical patent/CN117298092A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
CN202311053636.8A 2016-06-08 2017-06-06 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 Pending CN117298092A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08
US62/347,103 2016-06-08
PCT/CN2017/087341 WO2017211274A1 (en) 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
CN201780036000.9A CN110300581B (zh) 2016-06-08 2017-06-06 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780036000.9A Division CN110300581B (zh) 2016-06-08 2017-06-06 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途

Publications (1)

Publication Number Publication Date
CN117298092A true CN117298092A (zh) 2023-12-29

Family

ID=60577583

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311053636.8A Pending CN117298092A (zh) 2016-06-08 2017-06-06 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
CN201780036000.9A Active CN110300581B (zh) 2016-06-08 2017-06-06 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780036000.9A Active CN110300581B (zh) 2016-06-08 2017-06-06 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途

Country Status (12)

Country Link
US (2) US11406616B2 (https=)
EP (1) EP3468551A4 (https=)
JP (2) JP6872805B2 (https=)
KR (1) KR20190017873A (https=)
CN (2) CN117298092A (https=)
AU (1) AU2017277005B2 (https=)
CL (1) CL2018003537A1 (https=)
MX (1) MX2018015188A (https=)
NZ (1) NZ749389A (https=)
SG (1) SG11201810580PA (https=)
TW (1) TWI749016B (https=)
WO (1) WO2017211274A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
JP7685134B2 (ja) * 2019-11-27 2025-05-29 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
WO2022263624A1 (en) * 2021-06-18 2022-12-22 Sunregen Healthcare Ag Novel compounds for the treatment and prevention of neurological complications of viral infections
JP2023061448A (ja) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
US20260060952A1 (en) * 2022-10-02 2026-03-05 Refine Holdings Co., Ltd. Prophylactic, Progression Inhibitor, Ameliorant for Visual Field Defect Disorders, Light-Induced Ocular Tissue Disorders and Related Disorders, and Food Product

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781438A (zh) * 2009-12-30 2012-11-14 贝勒研究院 用于阿尔茨海默病和脑衰老的补给疗法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
CA1244772A (en) 1983-06-21 1988-11-15 Kuniaki Adachi Cell-stimulating composition
JPH02247125A (ja) 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
AU2001264079A1 (en) 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
US8399515B2 (en) 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
JP4334956B2 (ja) 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
CA2700431A1 (en) 2006-09-26 2008-04-03 Baylor Research Institute Use of odd-chain fatty acids in the modulation of cellular catabolism
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR100829729B1 (ko) 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
PT2299998T (pt) 2007-11-02 2018-04-02 Prometic Pharma Smt Ltd Acidos gordos e glicerídeos de cadeia média como agentes nefroprotetores
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
MX337605B (es) * 2010-01-08 2016-03-10 Catabasis Pharmaceuticals Inc Derivados de fumarato de acido graso y sus usos.
CN102883733B (zh) * 2010-02-10 2014-08-13 奥力榨油化株式会社 Age生成抑制剂
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
JP2013528648A (ja) 2010-06-14 2013-07-11 ベイラー リサーチ インスティテュート 成人ポリグルコサン小体病（ａｐｂｄ）を処置するためのトリヘプタノイン食
EP2407155B1 (en) * 2010-07-15 2012-12-26 Hybrigenics S.A. Formulations of inecalcitol
CN103945840A (zh) 2011-08-26 2014-07-23 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
CN102526643B (zh) * 2012-03-22 2013-09-11 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
CA2894456C (en) 2012-12-13 2022-06-28 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
CN117502539A (zh) * 2013-08-02 2024-02-06 施韦特-莫迪国际公司 包含经重构植物材料的可食用产品
ES2774321T3 (es) 2013-11-14 2020-07-20 Univ Queensland Trastornos neurodegenerativos y métodos de tratamiento y diagnóstico de los mismos
CN103641713B (zh) 2013-11-15 2015-10-21 浙江大学 甘油单酯衍生物的制备方法及应用
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CN105381182A (zh) 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用
EP3383382A1 (en) 2015-12-04 2018-10-10 Nestec S.A. Method for improving cognition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781438A (zh) * 2009-12-30 2012-11-14 贝勒研究院 用于阿尔茨海默病和脑衰老的补给疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张帼威，等: ""狭叶瓶尔小草化学成分的研究"", 天然产物研究与开发, 31 December 2010 (2010-12-31), pages 1006 - 1008 *
王福海，等: "《硬脂酸及脂肪酸衍生物生产工艺》", 31 May 1999, 轻工业出版社, pages: 2 *

Also Published As

Publication number Publication date
JP2021113204A (ja) 2021-08-05
WO2017211274A1 (en) 2017-12-14
NZ749389A (en) 2022-12-23
EP3468551A4 (en) 2020-01-22
CL2018003537A1 (es) 2019-05-03
AU2017277005A1 (en) 2019-01-17
AU2017277005B2 (en) 2022-12-22
CA3026152A1 (en) 2017-12-14
KR20190017873A (ko) 2019-02-20
US20190255129A1 (en) 2019-08-22
CN110300581B (zh) 2023-09-08
EP3468551A1 (en) 2019-04-17
JP6872805B2 (ja) 2021-05-19
US11406616B2 (en) 2022-08-09
US20220362197A1 (en) 2022-11-17
SG11201810580PA (en) 2018-12-28
US12594255B2 (en) 2026-04-07
CN110300581A (zh) 2019-10-01
TWI749016B (zh) 2021-12-11
MX2018015188A (es) 2019-08-21
JP2019518034A (ja) 2019-06-27
TW201801720A (zh) 2018-01-16

Similar Documents

Publication Publication Date Title
CN110300581B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
RS59048B1 (sr) Terapeutski agensi za neurodegenerativne bolesti
CA2978736A1 (en) Dosing regimen of tradipitant
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
CN103933058A (zh) 木犀草素-7-二葡萄糖醛酸苷在制备治疗视网膜退行性病变药物中的应用
WO2023034115A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
KR20170131543A (ko) 근위축성 측삭 경화증을 치료하기 위한 비오틴
US20260000685A1 (en) Pharmaceutical composition for preventing or treating degenerative brain diseases, comprising cannabinoids as active ingredient, and uses thereof
WO2019052629A1 (en) LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
CA3026152C (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP5417727B2 (ja) 網膜保護剤
HK40021759A (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
HK40021759B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
WO2022052016A1 (en) Pharmaceutical compositions and uses thereof in treating parkinson's disease
JPWO2006006617A1 (ja) 中枢神経疾患発症後の機能障害の回復促進剤
JP2007091727A (ja) 眼精疲労の予防又は緩和剤
JP5162859B2 (ja) 眼精疲労の予防又は緩和剤
WO2022241707A1 (en) Curcuminoid-rich oil extract, its preparation method and uses for treating diseases associated with neuron injury
Chaudhary et al. A review on Parkinson’s disease: overview and management
WO2025194157A2 (en) Therapeutic combinations for mitochondrial and other disorders
CN117529311A (zh) 治疗和预防病毒感染相关的神经系统并发症的新的化合物
WO2025208209A1 (en) Use of ibogaine in the treatment of central nervous system stroke
TW202103679A (zh) 一種落葵萃取物用於製備預防或治療神經系統疾病組合物的用途
Vgenopoulou et al. Melatonin levels in Alzheimer disease
US20180055901A1 (en) Regulation of Brain Biogenic Amines Associated with Depression by a Formulation from Botanical Source

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination